Indication Tooltip

LORBRENA® (lorlatinib) is a prescription medicine that is used to treat people with non-small cell lung cancer (NSCLC)

  • that is caused by an abnormal anaplastic lymphoma kinase (ALK) gene, and
  • that has spread to other parts of the body, and
  • who have taken the medicine:
    • alectinib, or ceritinib, or
    • both crizotinib and at least 1 other medicine to treat NSCLC that is caused by the ALK gene, and
  • that is no longer responding to these treatments.

It is not known if LORBRENA is safe and effective in children.

The effectiveness of LORBRENA is based on a study that measured tumor response rate and duration of response. There is an ongoing study to find out how LORBRENA works over a longer period of time.

Help identifying resources for eligible patients without any form of healthcare coverage:

Help finding coverage

Free medicine through the Pfizer Patient Assistance§ Program, or at a savings through the Pfizer Savings Program||

§The Pfizer Patient Assistance Program is a joint program of Pfizer Inc. and the Pfizer Patient Assistance Foundation.

The Pfizer Patient Assistance Foundation is a separate legal entity from Pfizer Inc., with distinct legal restrictions.

||The Pfizer Savings Program is not health insurance. For more information, call the toll-free number: 1-877-744-5675.

There are no membership fees to participate in this program. Estimated savings are 50% and depend on such factors as the particular drug purchased, amount purchased, and the pharmacy where purchased.

Pfizer Oncology Together Call 1-877-744-5675 Visit PfizerOncologyTogether.com